FEIBA prophylaxis in haemophilia patients: A clinical update and treatment recommendations

Haemophilia

Volumn 16, Issue 1, 2010, Pages 80-89

  Perry, D ^a   Berntorp, E ^b   Tait, C ^c   Dolan, G ^d   Holme, P A ^e   Laffan, M ^f   Lassila, R ^g   Mumford, A ^h   Pasi, J ⁱ   Wilde, J ^j   Will, A ^k   Yee, T T ^l  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c GLASGOW ROYAL INFIRMARY   (United Kingdom)

^d QUEEN S MEDICAL CENTRE   (United Kingdom)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f HAMMERSMITH HOSPITAL   (United Kingdom)

^g HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^h UNIVERSITY OF BRISTOL   (United Kingdom)

ⁱ ROYAL LONDON HOSPITAL   (United Kingdom)

^j UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^k ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^l ROYAL FREE HOSPITAL   (United Kingdom)

more..

Author keywords

Bypassing agents; Factor VIII inhibitors; FEIBA; Haemophilia; Inhibitors; Prophylaxis

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9;

ARTICLE; BLEEDING; BREAKTHROUGH BLEEDING; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG UTILIZATION; EVIDENCE BASED MEDICINE; HEMARTHROSIS; HEMOPHILIA A; HEMOPHILIA B; HUMAN; MEDICAL SPECIALIST; PATIENT CARE; PATIENT MONITORING; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; THROMBOSIS; TREATMENT DURATION;

ADOLESCENT; ADULT; BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION FACTORS; CHILD; CHILD, PRESCHOOL; HEMOPHILIA A; HEMOPHILIA B; HEMORRHAGE; HUMANS; IMMUNE TOLERANCE; INFANT; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; YOUNG ADULT;

EID: 73949133069     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2009.02104.x     Document Type: Article

References (45)

1. Frequently Asked Questions (FAQs) about hemophilia. http://www.wfh.org, Available at: (last accessed on 7 October 2008)
2. Hemophilia basics. http://www.hemophilia-information.com, Available at: (last accessed on 7 October 2008)
3. Fischer K, van der Bom JG, Molho P. Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome. Haemophilia 2002, 8:745-52.
4. Panicker J, Warrier I, Thomas R, Lusher JM. The overall effectiveness of prophylaxis in severe haemophilia. Haemophilia 2003, 9:272-8.
5. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study for outcomes for severe factor VIII deficient haemophiliacs. J Intern Med 1994, 236:391-9.
6. Ehrenforth S, Kreutz W, Scharrer I. Incidence of development of factor VIII and factor IX inhibitors in hemophiliacs. Lancet 1992, 339:594-8.
7. Triemstra M, Rosendaal FR, Smit C, Van der Ploeg HM, Briët E. Mortality in patients with hemophilia. Changes in a Dutch population from 1986 to 1992 and 1973 to 1986. Ann Intern Med 1995, 123:823-7.
8. Darby SC, Keeling DM, Spooner RJ. UK Haemophilia Center Doctors' Organization (UKHCDO). The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-1999. J Thromb Haemost 2004, 2:1047-54.
9. Key NS. Inhibitors in congenital coagulation disorders. Br J Haematol 2004, 127:379-91.
10. Summary of Product Characteristics 2007, Newbury, Baxter Healthcare Ltd
11. Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia 2002, 8:83-90.
12. Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2004, 2:1700-8.
13. DiMichele D. Inhibitors: resolving diagnostic and therapeutic dilemmas. Haemophilia 2002, 8:280-7.
14. Negrier C, Goudemand J, Sultan Y. Multicenter retrospective study on the utilization of FEIBA in France in patients with Factor VIII and factor IX inhibitors. Thromb Haemost 1997, 77:1113-9.
15. Ewing N. Anamnestic responses in haemophilia patients with inhibitors on continuous prophylaxis with factor VIII inhibitor bypass activity, vapour heated (FEIBA VH) [abstract]. J Thromb Haemost 2005, 3:P2036.
16. Hilgartner MW, Knatterud GL. The use of factor eight inhibitor bypass activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. Blood 1983, 61:36-40.
17. Berntorp E, Astermark J, Bjorkman S. Consensus perspectives on prophylactic therapy for haemophilia: a summary statement. Haemophilia 2003, 9:1-4.
18. Nilsson IM, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992, 232:25-32.
19. Liesner RJ, Khair K, Hann IM. The impact of prophylactic treatment on children with severe haemophilia. Br J Haematol 1996, 92:973-8.
20. Fisher K, Astermark J, Van Den Bom JG. Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen. Haemophilia 2002, 8:753-60.
21. Manco-Johnson MJ, Abshire TC, Shapiro AD. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007, 357:535-44.
22. Royal S, Schramm W, Berntorp E. for the European haemophilia economics study group. Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients. Haemophilia 2002, 8:44-50.
23. Berntorp E, Boulyjenkov V, Brettler D. Modern treatment of haemophilia. Bull World Health Organ 1995, 73:691-701.
24. Medical and Scientific Advisory Council Recommendation Concerning Prophylaxis (Regular administration of clotting factor concentrate to prevent bleeding). 2006, MASAC Recommendation 170, New York, National Hemophilia Foundation
25. Srivastava A, Giangrande P, Poon MC, Chua M, McCraw A, Wiedel J. Guidelines for the management of hemophilia. http://www.wfh.org/2/docs/Publications/Diagnosis_and_Treatment/Guidelines_Mng_Hemophilia.pdf, Available at: (last accessed on 6 March 2007)
26. Report on the Universal Data Collection Program 2008 Atlanta, GA, Centers for Disease Control and Prevention
27. Chambost H, Ljung R. Changing pattern of care of boys with haemophilia in western European countries. Haemophilia 2005, 11:92-9.
28. Geraghty S, Dunkley T, Harrington C, Lindvall K, Maahs J, Sek J. Practice patterns in haemophilia A therapy - global progress towards optimal care. Haemophilia 2006, 12:75-81.
29. Leissinger C, Wulff K, Abdou A. Inhibitor prevalence and association with morbidity in severe hemophilia A patients. Blood 2001, 98:535a.
30. Scalone L, Mantovani LG, Mannucci PM, Gringeri A. Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors. Haemophilia 2006, 12:154-62.
31. Valentino L. FEIBA Prophylaxis is Cost-Effective for the Pediatric Patient Poster presented at: XXVII International Congress of the World Federation of Hemophilia, May 21-25, 2006, Vancouver, Canada
32. Siegmund B, Richter H, Pollmann H. Prophylactic treatment with FEIBA of a haemophilia A patient with inhibitor: what are the costs, what are the benefits? Haemophilia 2005, 11:638-41.
33. Knight C. Health economics of treating haemophilia A with inhibitors. Haemophilia 2005, 11:11-7.
34. Valentino L. Assessing the Benefits of FEIBA Prophylaxis in Hemophilia Patients with Inhibitors: A Meta-Analysis Poster presented at: XXVIII International Congress of the World Federation of Hemophilia 2008. Abstract 08 PO 73, Istanbul, Turkey
35. Kreuz W, Escuriola-Ettinghausen C, Mentzer D. Immune tolerance induction (ITI) and factor VIII inhibitor bypass activity (FEIBA) for prophylaxis in patients with high-responding inhibitors [abstract]. Ann Hematol 2001, 80:138a.
36. Kreuz W, Escuriola-Ettinghausen C, Martinez I, Mentzer D, Figura S, Klarman D. Efficacy and safety of factor VIII inhibitor bypass activity (FEIBA) for long-term prophylaxis in patients with high-responding inhibitors [abstract 1140]. Blood 2000, 96:265a.
37. Hilgartner MW, Makipernaa A, DiMichele DM. Long-term FEIBA prophylaxis does not prevent progression of existing joint disease. Haemophilia 2003, 9:261-8.
38. Escuriola-Ettinghausen C, Martinez Sager I, Funk MB. Long-term prophylaxis with FEIBA in patients with high-responding inhibitors [abstract]. J Thromb Haemost 2003, 1:P1628.
39. Saxena K, Hawk S, Stevens B, Sexauer C. Long-term clinical experience with FEIBA VH in hemophilia patients with inhibitors [abstract]. J Thromb Haemost 2005, 3:P0838.
40. Leissinger CA, Becton DL, Ewing NP, Valentino LA. Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors. Haemophilia 2007, 13:249-55.
41. Valentino LA. The benefits of prophylactic treatment with APCC in patients with haemophilia and high-titre inhibitors: a retrospective case series. Haemophilia 2009, 15:733-42.
42. DiMichele D, Negrier C. A retrospective postlicensure survey of FEIBA efficacy and safety. Haemophilia 2006, 12:352-62.
43. Ewenstein B. Poster presented at: XXVI International Congress of the World Federation of Hemophilia. 2004, October 17s-21
44. Schino L, Mancuso G, Morfini M, Piseddu G, Sbrighi PS. APCC (FEIBA) Home Therapy Retrospective Survey in Long-Term Secondary Prophylaxis on 4 Hemophilia A Patients With Factor VIII Inhibitor 2006, Poster presented at XXVII International Congress of the World Federation of Hemophilia; May 21-5, Vancouver, Canada
45. Varadi K, Negrier C, Berntorp E. Monitoring the bioavailability of FEIBA with a thrombin generation assay. J Thromb Haemost 2003, 1:2374-80.